Overview
BFI Co., LLC - identified as a ten percent owner of Phibro Animal Health Corp (NASDAQ: PAHC) - completed a sequence of stock sales between March 17 and March 19, 2026, disposing of 19,980 shares of Class A Common Stock for total proceeds of approximately $1.19 million. The trades were carried out under a Rule 10b5-1 trading plan that BFI adopted on December 11, 2025.
Transaction details
The aggregate sales were executed at prices spanning $51.659 to $53.6436. The individual executions by date and lot were recorded as follows:
- March 17 - 5,280 shares sold at a weighted average price of $51.659; prices in that lot ranged from $51.26 to $52.13.
- March 18 - 4,311 shares sold at a weighted average price of $51.798; prices in that lot ranged from $51.29 to $52.21.
- March 18 - an additional 3,598 shares sold at a weighted average price of $53.0348; prices ranged from $52.35 to $53.295.
- March 18 - another 2,651 shares sold at a weighted average price of $53.6436; prices ranged from $53.365 to $53.88.
- March 19 - 1,939 shares sold at a weighted average price of $51.7841; prices ranged from $51.19 to $52.18.
- March 19 - 4,977 shares sold at a weighted average price of $52.7864; prices ranged from $52.195 to $53.125.
- March 19 - 124 shares sold at $53.24.
Holdings and governance
After these sales, BFI Co., LLC directly holds 73,320 shares of Class A Common Stock. Jack Bendheim - who serves as a director and officer (President and CEO) of Phibro Animal Health Corp and is also identified as a ten percent owner of the company - exercises voting and dispositive power over BFI. As a result, he may be deemed to share voting and investment power over the securities held by BFI. Mr. Bendheim also holds 16,840 shares directly.
Market context and valuation
The stock is trading at $52.38, which the filing notes sits close to its 52-week high of $56.30, following a 143% gain over the past year. An InvestingPro analysis cited in the filing indicates the shares may be overvalued at current levels, referencing a price-to-earnings ratio of 23.42 and a market capitalization of $2.13 billion.
Recent financial results
Phibro Animal Health Corporation reported fiscal second-quarter 2026 results that outperformed consensus expectations in the period covered by the filing. The company posted earnings per share of $0.87 versus a forecasted $0.68, a 27.94% earnings surprise. Revenue for the quarter reached $373.9 million, topping the anticipated $355.24 million by 5.25%. The filing notes that the strong earnings and revenue performance has drawn analyst attention, although no specific upgrades or downgrades were provided in the material.
What the filing shows - and what it does not
The sale was executed under a pre-established Rule 10b5-1 arrangement adopted December 11, 2025, which the filing explicitly identifies as the mechanism for the trades. The disclosure also documents the precise lot-level execution prices and weighted averages detailed above. The filing does not provide commentary on the motivation for the sales beyond the existence of the trading plan, and it does not disclose analyst actions in response to the Q2 results beyond noting broader attention from analyst firms.
Sectors affected
- Animal health and animal nutrition markets - direct exposure through Phibro's business.
- Equity markets and corporate governance - insider transactions and Rule 10b5-1 plan activity.
This report presents the facts disclosed in the trade filing and the company’s financial release without extrapolating beyond the information provided in those documents.